Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Alnylam
Alnylam
With trial win, Alnylam to seek approval for first treatment of rare kidney disease
Biopharma Dive
Tue, 12/17/19 - 10:29 am
Alnylam
lumasiran
clincial trials
RNAi
kidney disease
Primary Hyperoxaluria
5 New Drug Approvals the FDA Gave Top Priority
Motley Fool
Sat, 11/30/19 - 11:22 pm
FDA
drug approvals
Global Blood Therapeutics
Oxbryta
Alnylam
Givlaari
BeiGene
Brukinsa
Vertex Pharmaceuticals
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
RAPS.org
Wed, 11/27/19 - 12:39 pm
FDA
Vertex Pharmaceuticals
Trikafta
Novartis
Adakveo
Alnylam
Givlaari
BeiGene
Brukinsa
Global Blood Therapeutics
Oxbryta
drug approvals
Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class
Motley Fool
Sat, 11/23/19 - 04:05 pm
RNAi
Givlaari
Alnylam
FDA's rapid review pace nets an early approval for Alnylam's second drug
Biopharma Dive
Wed, 11/20/19 - 10:51 pm
FDA
Alnylam
Givlaari
givosiran
RNAi
porphyria
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
Yahoo/Benzinga
Sun, 11/17/19 - 08:47 pm
AHA
The Medicines Company
Intrexon
Alnylam
Pieris
Roche
These Biotechs Were Focused on One Line on Pfizer’s Earnings Report
Motley Fool
Thu, 10/31/19 - 11:51 pm
Pfizer
Vyndaqel
Alnylam
Akcea Therapeutics
Ionis Pharmaceuticals
Eidos Therapeutics
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
EP Vantage
Sat, 10/19/19 - 01:36 pm
Novartis
fevipiprant
severe asthma
Alnylam
lumasiran
Primary Hyperoxaluria
Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst
Fierce Pharma
Fri, 10/18/19 - 07:45 pm
Pfizer
tafamidis
FDA
Vyndaqel
Alnylam
Ionis
ATTR amyloidosis
Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn
Fierce Pharma
Tue, 07/9/19 - 06:32 pm
Ionis
Tegsedi
RNAi
Alnylam
Onpattro
NICE
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
Xconomy
Mon, 05/20/19 - 09:41 am
The Medicines Company
Alnylam
inclisiran
Can Pfizer Leap Over the Competition With This Potential Blockbuster?
Motley Fool
Wed, 05/8/19 - 10:03 am
Pfizer
Vyndamax
tafamidis
ATTR
Alnylam
Onpattro
Akcea Therapeutics
Tegsedi
Eidos Therapeutics
AG10
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
Xconomy
Mon, 05/6/19 - 10:54 am
FDA
Pfizer
tafamidis
Vyndaqel
Vyndamax
ATTR
Alnylam
Akcea
Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock
Endpoints
Fri, 05/3/19 - 10:52 pm
Sanofi
Alnylam
Alnylam posts strong Onpattro sales as competition heats up
Biopharma Dive
Thu, 05/2/19 - 08:12 pm
Alnylam
Onpattro
earnings
Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More
Xconomy
Sun, 04/21/19 - 12:16 am
FDA
CRISPR
gene therapy
Achaogen
Allergan
Alnylam
Adverum Biotechnologies
Blackstone Life Sciences
Alnylam's givosiran reduces mean porphyria attacks by 74% in Phase III
BioCentury
Fri, 04/12/19 - 11:33 pm
Alnylam
FDA
givosiran
acute hepatic porphyria
Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success
Endpoints
Thu, 04/11/19 - 10:11 am
Regeneron
Alnylam
R&D
Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases
Xconomy
Mon, 04/8/19 - 09:56 am
Alnylam
Regeneron
RNAi
eye health
brain diseases
2 Biotechs With Big Dates in April
Motley Fool
Sat, 03/30/19 - 01:04 pm
Alnylam
EASL
Intercept Pharmaceuticals
Onpattro
givosiran
NASH
Ocaliva
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »